Data protection Impressum

Biotech

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.

Cellestia Biotech receives CHF 2 million for its pioneering GvHD prevention therapy

23 January 2024

STALICLA has developed the first neurodevelopmental disorder-specific precision medicine platform with an initial application in autism spectrum disorder (ASD).

STALICLA secures USD 17.4 million to propel neuro precision medicine

22 January 2024

For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation with economic growth.

The remarkable chemical-pharmaceutical industry in the canton of Valais

This funding and partnership with the ADDF place GliaPharm at the forefront of developing effective treatments for Alzheimer’s, offering new hope in the fight against this challenging neurodegenerative disease.

GliaPharm receives USD 4.2 million to propel Alzheimer’s treatment development

20 December 2023

Top Stories Western Switzerland

Top Stories from Western Switzerland (October-December 2023)

19 December 2023

Cytiva’s recent move underlines Western Switzerland’s Health Valley region's growing significance as a hub for healthcare technology.

Cytiva’s strategic expansion in Western Switzerland’s Health Valley

11 December 2023

Siegfried’s Evionnaz site currently employs 380 professionals and is in the process of constructing a new R&D building, which is set to double the company's development capacity and create around 40 new jobs.

Siegfried, a Swiss leader taking innovations to industrial scale for the pharmaceutical industry

4 December 2023

LAGOSTA specializes in the sustainable farming of the European spiny lobster, converting byproducts in unique highly valuable products and setting up a series of ecological programs.

Vaud-based LAGOSTA and global giant Merck collaborate on chitosan distribution

2 November 2023

This strategic partnership will allow Fapon to research, develop, make, and sell PSP materials and test solutions using the chemiluminescence immunoassay (CLIA) in the Chinese market.

Abionic and Lascco partner with Fapon for sepsis diagnosis in China

2 November 2023

Novochizol technology quantitatively transforms single linear chitosan molecules into cross-linked, uniformly sized nanospheres.

EPFL and Novochizol to collaborate on designing more efficient immunotherapies

2 November 2023

1 … 5 6 7 8 9 10 11 12 13 … 20